Our Portfolio
![[yeda]Logo 2.png](https://static.wixstatic.com/media/8764fd_50a584678e4640b5b1c46579c496f249~mv2.png/v1/crop/x_0,y_44,w_1071,h_480/fill/w_980,h_439,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/%5Byeda%5DLogo%202.png)
A personalized medicine startup helping users prevent sudden glycemic spikes and manage metabolic conditions such as type 2 diabetes, overweight, and obesity. By combining artificial intelligence with gut microbiome insights, Yeda predicts individual glycemic responses to each meal. While inspired by global success stories, Yeda is purpose-built for the unique needs of the LATAM population, starting in Brazil.
Our first product is a mobile app that integrates food logging, continuous glucose monitoring, and bioimpedance analysis to provide real-time, personalized dietary recommendations. This empowers users to make practical, daily adjustments that stabilize glucose levels, improve body composition, and enhance overall health. We are also building a proprietary, region-specific dataset and training our own predictive engine—an asset no international player can offer in LATAM.
Yeda has partnered with Hospital Albert Einstein for validation and distribution, positioning us to lead the precision health movement across the region. We operate under a B2B SaaS model, offering private clinics and fitness chains scalable tools for metabolic health management. As GLP-1 therapies like Ozempic reshape the landscape, Yeda is uniquely positioned to complement this trend. This is how we aim to lead LATAM into the next era of AI-powered, precision healthcare.
Fernando Slamovitz
CEO
Lorenza Vecino Schandy
CTO
Juan Elenter
CPO